2021
DOI: 10.1038/s41388-021-01669-w
|View full text |Cite
|
Sign up to set email alerts
|

Correction to: Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…25 Moreover, adenosine deaminase acting on RNA 1 (ADAR1) and DExH-Box Helicase 9 work together to prevent the recognition of self-dsRNAs by innate immune sensors in breast cancer cells. 29,30 Despite the pathological relevance and therapeutic potential of cellular dsRNAs, the repertoire of dsRBPs remains largely elusive. The current golden standard of systemic identification of RBPs relies on ultraviolet (UV) crosslinking and pull-down with oligo-dT beads.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…25 Moreover, adenosine deaminase acting on RNA 1 (ADAR1) and DExH-Box Helicase 9 work together to prevent the recognition of self-dsRNAs by innate immune sensors in breast cancer cells. 29,30 Despite the pathological relevance and therapeutic potential of cellular dsRNAs, the repertoire of dsRBPs remains largely elusive. The current golden standard of systemic identification of RBPs relies on ultraviolet (UV) crosslinking and pull-down with oligo-dT beads.…”
Section: Introductionmentioning
confidence: 99%
“…25 Moreover, adenosine deaminase acting on RNA 1 (ADAR1) and DExH-Box Helicase 9 work together to prevent the recognition of self-dsRNAs by innate immune sensors in breast cancer cells. 29,30…”
Section: Introductionmentioning
confidence: 99%